Drug Profile
Influenza virus vaccine quadrivalent - Novavax
Alternative Names: Influenza virus-like particle vaccine quadrivalent - Novavax; NannoFlu; Novavax quadrivalent vaccine; Quad-NIV; Quadrivalent seasonal virus-like particle (VLP) influenza vaccine (recombinant) - Novavax; Quadrivalent VLP vaccine - Novavax; Recombinant quadrivalent seasonal influenza vaccine - Novavax; VLP-based quadrivalent seasonal influenza vaccine - NovavaxLatest Information Update: 14 Nov 2022
Price :
$50
*
At a glance
- Originator Novavax
- Class Influenza virus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 04 Nov 2022 Novavax terminates a phase II trial in Influenza virus infections (Prevention, In the elderly) in USA (IM) (NCT03658629)
- 26 Feb 2021 Phase II development is still ongoing for Influenza virus infections (Prevention, In the elderly) in USA (IM) (NCT03658629)
- 26 Apr 2019 Novavax completes a phase II trial in Influenza virus infections (Prevention, In the elderly) in USA (IM) (NCT03658629)